Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 3/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.47 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10136051 | 1.00 | NPC1 (0.51) | NPC1RAB9ACTSSCTSKCTSL | |
| SCHEMBL10195137 | 0.97 | NPC1 (0.54) | NPC1RAB9ACTSSCTSKCTSL | |
| SCHEMBL23446208 | 0.97 | NPC1 (0.54) | NPC1RAB9ACTSSCTSKCTSL | |
| SCHEMBL18495333 | 0.86 | ACE (0.66) | CTSSCTSKCTSLCTSBATM | |
| SCHEMBL11862942 | 0.86 | ACE (0.66) | CTSSCTSKCTSLCTSBATM | |
| SCHEMBL24141040 | 0.86 | IDO1 (0.45) | NPC1RAB9ACTSSCTSKCTSL | |
| SCHEMBL27406736 | 0.86 | ATM (0.60) | CTSSCTSKCTSLCTSBATM | |
| SCHEMBL19557762 | 0.85 | ACE (0.56) | CTSSCTSKCTSLCTSBATM | |
| SCHEMBL11860510 | 0.84 | CTSS (0.51) | CTSSCTSKCTSLCTSBATM | |
| SCHEMBL11860523 | 0.84 | CTSS (0.51) | CTSSCTSKCTSLCTSBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687467-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090137675-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090131322-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131322-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | NPC1 119/4885RAB9A 2485/4885CTSS 1737/4885 |
| US-20090137675-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | NPC1 119/4885RAB9A 2485/4885CTSS 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.